Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 98

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 98
---
 based on net loss, which is reported on the income statement as consolidated net loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. As such, the CODM uses cash forecast models in deciding how to invest into the biotech segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.

 15Table of Contents

The table below summarizes the significant expense categories regularly reviewed by the CODM for the six months ended June 30, 2025, and 2024:     Six Months  Six Months    Ended June  Ended June Operating Expenses  30,2025   30,2024 Research and development $909,746  $1,757,892 Sales and marketing  137,825   401,612 General and administrative  1,722,801   2,851,890 Total operating expenses  2,770,372   5,011,394          Operating loss  (2,770,372)  (5,011,394)         Other segment items (a)  508,130   6,541          Net loss $(2,262,242) $(5,004,853)         Reconciliation of net loss        Adjustments and reconciling items  -   -          Consolidated net loss $(2,262,242) $(5,004,853)  (a) Other segment items included in segment loss includes warrant expense, changes in warrant liability and interest income.

Note 13– Subsequent Events The Company has assessed operations through, August 14, 2025, the filing date of this Quarterly Report on Form 10-Q, and determined that there were no material subsequent events requiring adjustment to, or disclosure in, our consolidated financial statements for the six months ended June 30, 2025, other than the following: Issuance of Shares The Company issued a total